Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

August 16, 1999

COMPUTATION OF NET (LOSS) PER SHARE

Published on August 16, 1999


EXHIBIT 11

CYTOCLONAL PHARMACEUTICS INC.


COMPUTATION OF NET (LOSS) PER COMMON SHARE
(unaudited)




THREE MONTHS SIX MONTHS
ENDED JUNE 30, ENDED JUNE 30,
------------------------------ ------------------------------
1999 1998 1999 1998
------------ ------------ ------------ ------------

Net (loss) $ (827,000) $ (169,000) $ (1,912,000) $ (959,000)

Add cumulative preferred dividend (45,000) (51,000) (89,000) (103,000)
------------ ------------ ------------ ------------

NET (LOSS) USED FOR COMPUTATION $ (872,000) $ (220,000) $ (2,001,000) $ (1,062,000)

Weighted average number of common shares
outstanding--basic and diluted 10,342,000 9,727,000 10,305,000 9,286,000
------------ ------------

Net (loss) per common share--basic and
diluted $ (0.08) $ (0.02) $ (0.19) $ (0.11)





9